Literature DB >> 24094237

Molecular analysis of patients with weak D and serologic analysis of those with anti-D (excluding type 1 and type 2).

Bach-Nga Pham1, Michèle Roussel, Dominique Gien, Maryline Ripaux, Carine Carine, Pierre-Yves Le Pennec, Christine Andre-Botte.   

Abstract

Whether or not patients whose red blood cells (RBCs) carry certain weak D types produce anti-D, and if they do whether it is allo- or auto anti-D, remains controversial. The aim of this study was to determine the serologic features of anti-D in individuals expressing a weak D other than type 1 or type 2 and to assess whether the anti-D was an allo- or autoantibody. Serologic D typing and molecular analyses were performed on 748 individuals.Serologic characterization of anti-D included autologous controls,direct antiglobulin test, elution, and titration of anti-D before and after adsorption of serum onto autologous RBCs. From molecular analyses, 459 individuals exhibited a weak D type. We described seven novel RHD variant alleles. The most frequent types of weak D were type 1 (30.1%), type 2 (23.7%), type 4.0 (10.2%), type 4.2.2(20.3%), type 11 (3.9%), and type 15 (3.7%). Anti-D was identified in the sera of 9 of 47 individuals with weak D type 4.0, in 14 of 93 with weak D type 4.2.2, in 1 of 18 with weak D type 11, in 1 of 17 with weak D type 15, and in 1 weak D type 33 individual.Anti-D was demonstrated to be an alloantibody in weak D type 4.0, type 4.2.2, and type 15 individuals, but an autoantibody in weak D type 11 and type 33 individuals. In conclusion, only a complete serologic investigation of individuals with a given weak D type identified by molecular analysis allows concluding on the nature of the antibody. Transfusing weak D type 4.2.2 and type 15 patients with D- RBC units and proposing anti-D immunoprophylaxis to women with these weak D types should be considered.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24094237

Source DB:  PubMed          Journal:  Immunohematology        ISSN: 0894-203X


  6 in total

1.  A proposal for a rational transfusion strategy in patients of European and North African descent with weak D type 4.0 and 4.1 phenotypes.

Authors:  Willy A Flegel; Thierry Peyrard; Jacques Chiaroni; Christophe Tournamille; Déborah Jamet; France Pirenne
Journal:  Blood Transfus       Date:  2018-05-03       Impact factor: 3.443

2.  It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group.

Authors:  S Gerald Sandler; Willy A Flegel; Connie M Westhoff; Gregory A Denomme; Meghan Delaney; Margaret A Keller; Susan T Johnson; Louis Katz; John T Queenan; Ralph R Vassallo; Clayton D Simon
Journal:  Transfusion       Date:  2014-12-01       Impact factor: 3.157

3.  What constitutes the most cautious approach for a pregnant person with weak D type 4.0?

Authors:  Willy Albert Flegel; Melanie Bodnar; Gwen Clarke; Judith Hannon; Lani Lieberman
Journal:  CMAJ       Date:  2021-06-14       Impact factor: 8.262

4.  Proceed with care: the "uncommon" serologic weak D phenotypes.

Authors:  Willy Albert Flegel
Journal:  Blood Transfus       Date:  2021-07       Impact factor: 3.443

5.  Transfusion strategy for weak D Type 4.0 based on RHD alleles and RH haplotypes in Tunisia.

Authors:  Mouna Ouchari; Kshitij Srivastava; Houda Romdhane; Saloua Jemni Yacoub; Willy Albert Flegel
Journal:  Transfusion       Date:  2017-11-29       Impact factor: 3.157

6.  It's time to phase out "serologic weak D phenotype" and resolve D types with RHD genotyping including weak D type 4.

Authors:  Willy A Flegel; Gregory A Denomme; John T Queenan; Susan T Johnson; Margaret A Keller; Connie M Westhoff; Louis M Katz; Meghan Delaney; Ralph R Vassallo; Clayton D Simon; S Gerald Sandler
Journal:  Transfusion       Date:  2020-03-12       Impact factor: 3.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.